title: [Anti HCV in hemodialyzed patients: reduction of the prevalence and association with epidemiological variables].
abstract: In order to establish the present prevalence of HCV in hemodialyzed patients (HD) from the city of La Plata, and to know the association between the prevalence and different variables, we have studied 217 hemodialyzed patients belonged to the Hemodialysis Unit of a Public Hospital and other 7 private Units. Serological reactivity to Anti HCV and Anti HBc IgG were investigated in all of them, as well as age, sex, number of transfusions, the time under dialysis treatment, the use of erythropoietin and hepatitis episodes were taken into account. We have found a prevalence of Anti HCV of 18.4% which was significantly superior to the blood donors' prevalence (P < 0.01) and significantly inferior to the one found in 1993 in HD patients of the same city (p = 0.002). We have found an association between the presence of Anti HCV and transfusions exposure, as well as more hemodialysis time. Our results may agree with the ones that suggest the aminotransferases are not good markers for hepatocellular injuries in Anti HCV (R) HD patients.
authors.affiliation: Servicio de Gastroenterología (Unidad de Hepatología), Hospital Rodolfo Rossi, ciudad de la Plata.
authors.forename: M
authors.initials: M
authors.lastname: Padrone
authors.forename: O
authors.initials: O
authors.lastname: Corallini
authors.forename: D
authors.initials: D
authors.lastname: Cocozzella
authors.forename: M
authors.initials: M
authors.lastname: Malca
authors.forename: S
authors.initials: S
authors.lastname: Borzi
authors.forename: M
authors.initials: M
authors.lastname: Barrio
authors.forename: R E
authors.initials: RE
authors.lastname: Adrover
authors.forename: A M
authors.initials: AM
authors.lastname: Cuffini
authors.forename: C
authors.initials: C
authors.lastname: Gomez
authors.forename: A M
authors.initials: AM
authors.lastname: Giamona
authors.forename: G
authors.initials: G
authors.lastname: Brawlasky
authors.forename: P
authors.initials: P
authors.lastname: Newmann
authors.forename: M
authors.initials: M
authors.lastname: Dell Amo
authors.forename: E
authors.initials: E
authors.lastname: Fraquelli
authors.forename: J O
authors.initials: JO
authors.lastname: Curciarello
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects; D016036:Seroepidemiologic Studies
chemical_list: D018937:Hepatitis C Antibodies